Rising Rectal Cancer in Millennials and New Tools to Catch Colon Cancer Early
From cancer-sniffing dogs to liquid biopsies, new research highlights early detection breakthroughs and a growing colorectal cancer crisis in young adults.
Summary
Colorectal cancer is rising sharply among millennials, prompting researchers and clinicians to call it a medical crisis. This roundup covers several promising developments: cancer-sniffing dogs detecting seven early-stage cancers with over 90% accuracy, epigenetic changes linked to diet and pesticides driving colorectal cancer in younger people, and concerns that many patients are unknowingly discarding early diagnostic clues in their stool. A liquid biopsy tool showed strong ability to predict immunotherapy response in early breast cancer, while exercise and ibuprofen both showed potential to protect cognitive function during cancer treatment. Additionally, a GSK-3 beta inhibitor added to chemotherapy extended survival in metastatic pancreatic cancer from 7.2 to 10.1 months, offering a rare glimmer of progress in one of oncology's hardest-to-treat diseases.
Detailed Summary
Colorectal cancer trends are alarming health experts, with rectal cancer mortality rising significantly among millennials — a demographic not traditionally considered high-risk. This MedPage Today roundup aggregates recent findings across oncology that carry real implications for disease prevention, early detection, and treatment optimization.
One of the most striking findings involves cancer-detecting dogs. Trained animals identified seven types of early-stage cancer with greater than 90% accuracy, suggesting biological scent markers may offer a non-invasive screening pathway. Separately, Spanish researchers identified epigenetic changes driven by diet, tobacco use, and pesticide exposure as potential drivers of colorectal cancer in younger populations — pointing to modifiable lifestyle factors as meaningful prevention targets.
On the diagnostic front, liquid biopsy technology demonstrated the ability to predict whether high-risk early breast cancer patients would respond to immunotherapy, potentially sparing non-responders from unnecessary treatment. An investigational camera system also showed promise in helping surgeons assess lymph node involvement during cancer operations, which could improve staging accuracy and surgical outcomes.
For those undergoing cancer treatment, both exercise and ibuprofen showed preliminary potential to counteract cognitive side effects — commonly known as 'chemo brain' — offering accessible, low-cost interventions worth discussing with oncologists. Meanwhile, adding the GSK-3 beta inhibitor elraglusib to standard chemotherapy extended median overall survival in untreated metastatic pancreatic cancer from 7.2 to 10.1 months, a meaningful gain in a disease with historically poor prognosis.
Caveats apply throughout: this is a news roundup, not a single peer-reviewed study, and many findings are preliminary or from small trials. Readers should consult primary sources and healthcare providers before drawing clinical conclusions. Still, the convergence of early detection tools, lifestyle-linked cancer drivers, and novel therapeutics makes this a highly relevant update for longevity-focused individuals.
Key Findings
- Cancer-sniffing dogs detected seven early-stage cancer types with over 90% accuracy in a new study.
- Epigenetic changes from diet, tobacco, and pesticides may drive colorectal cancer in younger adults.
- Liquid biopsy predicted immunotherapy response in high-risk early breast cancer patients accurately.
- Adding elraglusib to chemotherapy extended metastatic pancreatic cancer survival from 7.2 to 10.1 months.
- Exercise and ibuprofen both showed potential to reduce cognitive side effects of cancer treatment.
Methodology
This is a curated news roundup by a senior editor at MedPage Today, aggregating recent oncology findings from multiple sources including peer-reviewed journals and institutional press releases. Source credibility is high given MedPage Today's clinical audience and editorial standards. Evidence quality varies across items, ranging from published trial data to preliminary announcements.
Study Limitations
This article is a brief roundup without deep methodological detail on individual studies; primary sources should be reviewed for sample sizes, study design, and statistical significance. Several findings are preliminary or from single institutions and have not yet been replicated. Readers should not interpret any single item as clinical guidance without consulting a healthcare provider.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.